These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11592343)

  • 1. A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients.
    Thomas RR; Dahut W; Harold N; Grem JL; Monahan BP; Liang M; Band RA; Cottrell J; Llorens V; Smith JA; Corse W; Arbuck SG; Wright J; Chen AP; Shapiro JD; Hamilton JM; Allegra CJ; Takimoto CH
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):215-22. PubMed ID: 11592343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.
    Siu LL; Oza AM; Eisenhauer EA; Firby PS; Thiessen JJ; Michael M; Wainman N; Manzo J; Feld R; Goldberg RA; Moore MJ
    J Clin Oncol; 1998 Mar; 16(3):1122-30. PubMed ID: 9508199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
    Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
    Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.
    Leguizamo J; Quinn M; Takimoto CH; Liang MD; Ismail AS; Pang J; Dahut W; Grem JL
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):333-8. PubMed ID: 12819941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.
    Dahut W; Harold N; Takimoto C; Allegra C; Chen A; Hamilton JM; Arbuck S; Sorensen M; Grollman F; Nakashima H; Lieberman R; Liang M; Corse W; Grem J
    J Clin Oncol; 1996 Apr; 14(4):1236-44. PubMed ID: 8648379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
    Eder JP; Supko JG; Lynch T; Bryant M; Vosburgh E; Shulman LN; Xu G; Kufe DW
    Clin Cancer Res; 1998 Feb; 4(2):317-24. PubMed ID: 9516917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study.
    Langevin AM; Casto DT; Thomas PJ; Weitman SD; Kretschmar C; Grier H; Pratt C; Dubowy R; Bernstein M; Blaney S; Vietti T
    J Clin Oncol; 1998 Jul; 16(7):2494-9. PubMed ID: 9667269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
    Vey N; Kantarjian H; Tran H; Beran M; O'Brien S; Bivins C; Giles F; Cortes J; Cheson B; Arbuck S; Estey E
    Ann Oncol; 1999 May; 10(5):577-83. PubMed ID: 10416008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.
    Takimoto CH; Dahut W; Marino MT; Nakashima H; Liang MD; Harold N; Lieberman R; Arbuck SG; Band RA; Chen AP; Hamilton JM; Cantilena LR; Allegra CJ; Grem JL
    J Clin Oncol; 1997 Apr; 15(4):1492-501. PubMed ID: 9193345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
    Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
    Minami H; Lad TE; Nicholas MK; Vokes EE; Ratain MJ
    Clin Cancer Res; 1999 Jun; 5(6):1325-30. PubMed ID: 10389915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
    Paz-Ares L; Kunka R; DeMaria D; Cassidy J; Alden M; Beranek P; Kaye S; Littlefield D; Reilly D; Depee S; Wissel P; Twelves C; O'Dwyer P
    Br J Cancer; 1998 Nov; 78(10):1329-36. PubMed ID: 9823974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
    Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
    Mani S; Iyer L; Janisch L; Wang X; Fleming GF; Schilsky RL; Ratain MJ
    Cancer Chemother Pharmacol; 1998; 42(1):84-7. PubMed ID: 9619763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.
    de Jonge MJ; Punt CJ; Gelderblom AH; Loos WJ; van Beurden V; Planting AS; van der Burg ME; van Maanen LW; Dallaire BK; Verweij J; Wagener DJ; Sparreboom A
    J Clin Oncol; 1999 Jul; 17(7):2219-26. PubMed ID: 10561279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
    Takimoto CH; Morrison G; Harold N; Quinn M; Monahan BP; Band RA; Cottrell J; Guemei A; Llorens V; Hehman H; Ismail AS; Flemming D; Gosky DM; Hirota H; Berger SJ; Berger NA; Chen AP; Shapiro JD; Arbuck SG; Wright J; Hamilton JM; Allegra CJ; Grem JL
    J Clin Oncol; 2000 Feb; 18(3):659-67. PubMed ID: 10653882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
    Eckhardt SG; Baker SD; Eckardt JR; Burke TG; Warner DL; Kuhn JG; Rodriguez G; Fields S; Thurman A; Smith L; Rothenberg ML; White L; Wissel P; Kunka R; DePee S; Littlefield D; Burris HA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Mar; 4(3):595-604. PubMed ID: 9533526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.